Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac342
In this study risankizumab treatment resulted in greater improvements in fatigue and pain than placebo. Prior to this finding the study aimed to evaluate the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial.
To achieve this aim adult PsA patients were randomised (1:1) to receive risankizumab 150mg or placebo. Their findings also highlighted that risankizumab treated patients reported greater improvements vs placebo in work productivity, suggesting real clinical efficacy in its use in PSA therapy.